Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
There have been complaints that after multiple reprocessing cycles the epoxy resin which holds the tcn electrode can exhibit signs of damage. in some cases this damage may result in the inability to fully remove blood and/or tissue residuals prior to cleaning and re-sterilizing the device. the failure to completely remove any blood and/or tissue from the tcn electrodes prior to re-sterilization creates a potential risk of infection and spread of blood borne pathogens to patients.
“We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”